Workflow
博美集团上涨4.63%,报8.025美元/股,总市值14.76亿美元

Core Insights - BGM's stock price increased by 4.63% to $8.025 per share, with a total market capitalization of $1.476 billion as of August 9 [1] - For the fiscal year ending March 31, 2025, BGM reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while net profit attributable to shareholders was a loss of $0.8612 million, a significant decrease of 307.79% compared to the previous year [1] Company Overview - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used not only for human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, which are key anticoagulants [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]